Table 3.

Viral elimination half-life as individual patient approach.

Control		Sub-group<160		Sub-group>160
Participant #	Half-life	Participant #	Half-life	Participant #	Half-life
1·1	7·70	1·4	11·5	1·3	2·39
1·6	3·01	1·10	4·33	1·5	1·03
1·11	7·70	1·15	5·78	1·13	0·99
1·12	2·31	2·1	7·70	2·3	1·08
1·16	5·33	2·5	13·86	5·1	1·14
2·2	3·85	1·21	4·33	1·19	1·05
2·4	6·93	5·5	4·95	3·1	2·24
2·6	5·33	5·9	4·08	5·6	0·32
5·4	9·90	5·13	0·36	1·22	6·93
1·20	7·70	5·15	5·78
5·7	2·31	5·16	4·33
5·10	4·08
Median	5·33		4·95		1·08
1q	3·22		4·33		1·01
3q	7·70		7·70		2·32
IQR	4·48		3·37		1·31
Mean (CI 95%)	5·51 (3·94,7·08)		6·09 (3·58,8·60)		1·91 (0·38,3·44)
SD	2·47		3·74		1·99